Coherus Oncology vs Invivyd
CHRS and IVVD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CHRS and IVVD compare
Invivyd is the larger company, worth 2.1 times as much as Coherus Oncology ($172M against $81.2M).
Coherus Oncology grew revenue faster over the last twelve months (44.4% versus 26.3% for Invivyd).
Invivyd keeps more of each dollar of sales as profit, with a net margin of −184% compared with −253% at Coherus Oncology.
Invivyd scores higher on the StockData Score (9 against 6 for Coherus Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CHRS | IVVD |
|---|---|---|
| Size and price | ||
| Market cap | $81.2M | $172M |
| Share price | $0.525 | $0.582 |
| Change, 1 year | −61.4% | −67.1% |
| Change, 5 years | −97.2% | −97.1% |
| Beta (5Y) | 1.37 | 1.41 |
| Employees | 147 | 122 |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.5× (better) | 2.9× |
| P/B | 3.2× | 0.9× (better) |
| FCF yield | – | −63.9% |
| Fair value | $0.853 | $0.954 |
| Margin of safety | 38.4% | 39.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 44.4% (better) | 26.3% |
| Revenue growth, 5Y average | −38.4% | – |
| Net income growth (TTM) | −188% | – |
| EPS growth, 5Y average | −2.5% | – |
| Profitability | ||
| Gross margin | 69.8% | – |
| Operating margin | −276% | −193% (better) |
| Net margin | −253% | −184% (better) |
| FCF margin | – | −188% |
| Return on equity | −241% | −95.9% (better) |
| Return on invested capital | – | −616% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −15.5× | – |
| Current ratio | 1.51 | 5.87 (better) |
| Altman Z-score | −14.06 | −4.53 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.23% |
| Shareholder yield | 0.00% (better) | −0.23% |
| Ownership | ||
| Held by institutions | 45.5% | 79.0% |
| Held by insiders | 1.3% | 16.7% |
| Insider net buying, 12 months | – | −$531K |
| Short interest, % of float | 8.3% | 14.7% |
Go deeper
- CHRS stock overview
- CHRS income statement
- CHRS valuation and score
- IVVD stock overview
- IVVD income statement
- IVVD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.